ALBERTO DIAZ: Open Payments
NPI 1659879344 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,172 in 29 payments from 11 companies in 2025. Trend: 2023 $99 · 2024 $26 · 2025 $1,172
Food & beverage: $1,073Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $284 |
| Actelion Pharmaceuticals US, Inc. | 4 | $276 |
| Amgen Inc. | 3 | $162 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| PFIZER INC. | 4 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $91 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: UPTRAVI, REPATHA, Ozempic, Wegovy, CAMZYOS, OPSUMIT, Kerendia, ELIQUIS.
Industry payments across FL — which companies pay providers there.
